Physician profile
Adam C Smith
NPI 1932604451
$2,378.92
in general payments reported to CMS, 2019-2025
20 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.79 · 2021: $192 · 2022: $348 · 2023: $558 · 2024: $638 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $483.67 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $288.76 | 2021-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $207.13 | 2022-2025 | Vraylar |
| Alkermes, INC. | $204.01 | 2021-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $180.75 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $161.46 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $155.03 | 2023-2025 | Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.95 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $108.85 | 2022-2024 | Ingrezza |
| Indivior INC. | $108.32 | 2022-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $83.56 | 2022-2024 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $71.14 | 2022 | |
| Eisai INC. | $42.30 | 2021 | |
| Allergan, INC. | $39.79 | 2019 | |
| Braeburn INC. | $29.60 | 2023 | Brixadi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $19.11 | 2021 | |
| Sage Therapeutics, LLC | $16.60 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.72 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $15.06 | 2025 | Qelbree |
| Neuronetics, INC. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.